Authors: Wade, Alan G.¹; Ford, Ian²; Crawford, Gordon¹; McMahon, Alex D.²; Nir, Tali³; Laudon, Moshe³; Zisapel, Nava⁴

Source: Current Medical Research and Opinion, Volume 23, Number 10, October 2007 , pp. 2597-2605(9)

Publisher: Informa Healthcare

Abstract:

Objective: Melatonin, the hormone produced nocturnally by the pineal gland, serves as a circadian time cue and sleep-anticipating signal in humans. With age, melatonin production declines and the prevalence of sleep disorders, particularly insomnia, increases. The efficacy and safety of a prolonged release melatonin formulation (PR-melatonin; Circadin 2 mg) were examined in insomnia patients aged 55 years and older.

Design: Randomised, double blind, placebo-controlled.

Setting: Primary care.

Methodology: From 1248 patients pre-screened and 523 attending visit 1, 354 males and females aged 55-80 years were admitted to the study, 177 to active medication and 177 to placebo. The study was conducted by primary care physicians in the West of Scotland and consisted of a 2-week, single blind, placebo run-in period followed by a 3-week double blind treatment period with PR-melatonin or placebo, one tablet per day at 2 hours before bedtime.

Main outcome measures: Responder rate (concomitant improvement in sleep quality and morning alertness on Leeds Sleep Evaluation Questionnaire [LSEQ]), other LSEQ assessments, Pittsburgh Sleep Quality Index (PSQI) global score, other PSQI assessments, Quality of Night and Quality of Day derived from a diary, Clinical Global Improvement scale (CGI) score and quality of life (WHO-5 well being index).

Results: Of the 354 patients entering the active phase of the study, 20 failed to complete visit 3 (eight PR-melatonin; 12 Placebo). The principal reasons for drop-out were patient decision and lost to follow-up. Significant differences in favour of PR-melatonin vs. placebo treatment were found in concomitant and clinically relevant improvements in quality of sleep and morning alertness, demonstrated by responder analysis (26% vs. 15%; p = 0.014) as well as on each of these parameters separately. A significant and clinically relevant shortening of sleep latency to the same extent as most frequently used sleep medications was also found (−24.3 vs.−12.9 minutes; p = 0.028). Quality of life also improved significantly (p = 0.034).

Conclusions: PR-melatonin results in significant and clinically meaningful improvements in sleep quality, morning alertness, sleep onset latency and quality of life in primary insomnia patients aged 55 years and over.

Trial registration: The trial was conducted prior to registration being introduced.

Keywords: INSOMNIA; MELATONIN; MORNING ALERTNESS; SLEEP LATENCY; SLEEP QUALITY

Document Type: Research article

DOI: http://dx.doi.org/10.1185/030079907X233098

Affiliations: 1: CPS Research, Glasgow, UK 2: Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK 3: Neurim Pharmaceuticals Ltd, Tel Aviv, Israel 4: Neurim Pharmaceuticals Ltd, Tel Aviv, Israel; Department of Neurobiochemistry, Tel Aviv University, Tel-Aviv, Israel

Publication date: 2007-10-01

More about this publication?

• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• General Information
• Journal Information
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Medicine (General)
• By this author: Wade, Alan G. ;  Ford, Ian ;  Crawford, Gordon ;  McMahon, Alex D. ;  Nir, Tali ;  Laudon, Moshe ;  Zisapel, Nava

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers